drugset
drugset / Trial / NCT05475210

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

NCT05475210 ↗

Phase 1 Unknown 9 enrolled Molecular Targeting Technologies, Inc. ClinSmart · collab
NaSequentialOpen-labelTreatment

Summary

This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.

Timeline

Start
2022-06-18
Primary completion
2024-12-31
Completion
2025-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DOTA-EB-TATE Peptide 1850 mbq Intravenous
Subject 177Lu-DOTA-EB-TATE Peptide 5550 mbq Intravenous

Indications

neuroendocrine neoplasm